Table 2

Serious infection rate in patients who received treatment with another biological DMARD

Overall (N  =  2578)Patients receiving any biological agent after rituximab treatment (n  =  185)Patients receiving TNF inhibitor after rituximab treatment (n  =  153)
Before other biological agentAfter other biological agentBefore other TNF inhibitorAfter other TNF inhibitor
Total exposure, patient-years5013186.05182.31150.87162.41
Serious infections, n2161310108
Serious infections/100 patient-years4.316.995.496.634.93
95% CI3.77 to 4.924.06 to 12.032.95 to 10.193.57 to 12.322.46 to 9.85
  • DMARD, disease-modifying antirheumatic drug; TNF, tumour necrosis factor.